EU MDR PMCF: Plan, Clinical Follow-Up & Reporting
Last reviewed:
Post-Market Clinical Follow-Up (PMCF) is a continuous, proactive process of collecting clinical data from the real-world use of a device after it is placed on the market.
Video guide
EU MDR PMCF: Plans, Reports and Timing
A guide to post-market clinical follow-up under the EU MDR, including PMCF plans, evaluation reports and timing.
Open video pageTranscript (English)
Does your device need PMCF? Under the EU MDR, every device needs a PMCF plan, or a justification for why PMCF does not apply. So what does PMCF actually do? PMCF is a continuous process that updates your clinical evaluation. You proactively collect clinical data from the device on the market, to confirm its safety and performance over its expected lifetime, and to detect emerging risks. How often? For Class III and implantable devices, the PMCF evaluation report must be updated at least once a year. The MDCG templates are 2020-7 for the plan, and 2020-8 for the report. And the findings travel. They feed your clinical evaluation and your risk management, and for Class IIa, IIb and III devices, the main findings also go into the PSUR. Start with three things. One: set PMCF objectives from your clinical evidence gaps. Two: if PMCF does not apply, justify it in the PMS plan. Three: schedule every PMCF evaluation report. Plan it, or justify it. Pure Global covers registration, in-country representation, quality systems, audits and cybersecurity, in more than 30 markets. Visit pureglobal.com.
What is Post-Market Clinical Follow-Up under the EU MDR?
Post-Market Clinical Follow-Up (PMCF) is a continuous, proactive process of collecting clinical data from the real-world use of a device after it is placed on the market. PMCF is required under the European Medical Device Regulation (EU MDR), defined in Annex XIV, Part B. It is a crucial part of your Post-Market Surveillance (PMS) system, which monitors a medical device’s safety and performance once it has been CE Marked and placed on the EU market. Data gathered through PMCF supports continuous clinical evaluation and must be incorporated into the device’s Technical Documentation and Clinical Evaluation Report (CER). It is also a vital component of your quality management system (QMS).
The primary goals of PMCF are to confirm the long-term safety and performance of the device, monitor the ongoing acceptability of known risks, identify any new risks or side effects, and ensure that the device's benefit-risk balance remains acceptable. PMCF also helps detect off-label use and verify that the device continues to be used as intended.
Planning your PMCF activities
The first step in the PMCF process is to develop a structured PMCF Plan. This document outlines the strategy and methods you will use to gather clinical data. PMCF data can include user surveys, literature reviews, registry data, or formal PMCF studies. You must explain why each method was selected and how it aligns with the specific safety and performance requirements for your device. The detailed structure and content of the PMCF Plan is published in MDCG 2020-7 “Post-market clinical follow-up (PMCF) Plan Template."
The scope of your PMCF activities should be proportionate to the device’s risk class and type. Manufacturers should perform a gap analysis to identify the clinical data they need, after the devices have been placed on the EU market. The PMCF Plan must include how to select appropriate data collection methods and sources and how to update risk management and CER accordingly. Any conclusion that PMCF is not applicable must be specifically justified in the technical documentation; low risk alone is not a blanket exemption. High-risk devices typically require more comprehensive PMCF plans and PMCF studies to demonstrate the device’s safety and performance.
PMCF reporting requirements
Once implemented, the results of your PMCF activities will be summarized in a PMCF Report, which is part of your ongoing updates to the CER. For Class III and implantable devices, MDR Article 61(11) requires the PMCF evaluation report to be updated at least annually. For other devices, set a justified schedule based on the plan, evidence gaps and risk; new safety or performance information can require an earlier update. There is no universal two-to-five-year PMCF reporting interval. PMCF data is also summarized in the PMS Report or Periodic Safety Update Report (PSUR), depending on your device class. The detailed content of the PMCF Report is published in MDCG 2020-8 “Post-market clinical follow-up (PMCF) Report Template."
Match the activity to the uncertainty
| Remaining question | Potential method | Limitation to control |
|---|---|---|
| Long-term implant performance | Registry or targeted follow-up study | Follow-up completeness and relevant endpoints |
| Use in the claimed setting | Structured user/clinical data collection | Selection bias and insufficient clinical outcome information |
| New risks or changed state of the art | Literature and surveillance analysis | Relevance to the actual device and population |
Specify objectives, methods, analysis, milestones and escalation thresholds before collecting data. Feed results into clinical evaluation, risk management and the PSUR; a questionnaire alone does not necessarily resolve a clinical evidence gap.
Official framework and connected work
Use the current MDR, IVDR and Commission guidance for the applicable legal text and interpretation. Start from the EU market-entry hub for the overall pathway; this guide addresses the specific task within that program.
For regulatory terminology and the authority framework, see the EU MDR.
Start planning your Post-Market Clinical Follow-up
Plan your device registration, local representation and ongoing compliance with Pure Global.

Frequently asked questions
PMCF is an ongoing process, and its methods depend on remaining clinical questions and risks. A dedicated study may be needed, but other justified methods can contribute; document why the chosen activities address the gaps.
No. Any conclusion that PMCF is not applicable needs a device-specific justification in the technical documentation. Low risk or established technology alone does not establish that no further clinical follow-up is needed.
MDR Article 61(11) specifies at least annual updates for Class III and implantable devices. For other devices, justify the schedule and update when new evidence or changes require it; avoid a blanket two-to-five-year rule.
Single Process,
Multiple Markets
When you partner with Pure Global, a single registration process opens doors to multiple countries. Our global subsidiaries make this streamlined path possible.
Let's Talk,
Anywhere You Are.
Whether looking for more information or ready to partner with us, we're here to guide you through every step of the regulatory process.
Contact us










